Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
about
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation.Follow the LEADER-Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial.Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trialEarly Combination Therapy with Oral Glucose-Lowering Agents in Type 2 Diabetes.Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry.Integrated cardiovascular safety: multifaceted considerations in drug development and therapeutic use.FGF1 - a new weapon to control type 2 diabetes mellitus.Comparative effects of microvascular and macrovascular disease on the risk of major outcomes in patients with type 2 diabetes.Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin.Impact of type 2 diabetes mellitus on in-hospital-mortality after major cardiovascular events in Spain (2002-2014).The Landscape of Glucose-Lowering Therapy and Cardiovascular Outcomes: From Barren Land to Metropolis.Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications.Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events.
P2860
Q33696974-FEAD6D13-AB49-4451-8081-50CC467BBE1EQ33871304-D8A4DDEB-0DEE-412E-93B8-9B80E8DAE650Q36288929-0491801E-FE68-464C-93A0-8564314B8506Q37427291-DC6987F6-10D0-425E-AC37-9C3878250014Q37736727-AD1E6229-0F98-4522-8D2C-79981FD1DD08Q38762377-5F561D48-7075-452D-8CDC-905700CE7A74Q38825446-71A91F33-F535-42A4-931D-EFEE7ACAA7E4Q39164190-C56A7B31-5116-4A5C-B262-9EB5950EDD6CQ39406663-28A2C039-E50A-4973-8495-D2BE082C82B9Q40105411-F75F36CA-1429-4999-9264-29FB23CFE47DQ41107105-3804200B-746F-418E-9EDD-0197C51575F0Q42374460-5164D8B1-787D-4B9D-81DA-40B2B333AB16Q47117670-69B898CB-013B-4646-86DA-71D8C73DF74FQ47367638-5FD50D01-4299-4DF6-BE7E-B90282954CA6Q48224536-74F93CD5-6A71-4C2F-968F-22E9F72073CFQ55049744-E47E5FC2-442A-48B3-8570-228E390B5B8E
P2860
Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice
description
2016 nî lūn-bûn
@nan
2016 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Continued efforts to translate ...... trials into clinical practice
@ast
Continued efforts to translate ...... trials into clinical practice
@en
Continued efforts to translate ...... trials into clinical practice
@nl
type
label
Continued efforts to translate ...... trials into clinical practice
@ast
Continued efforts to translate ...... trials into clinical practice
@en
Continued efforts to translate ...... trials into clinical practice
@nl
prefLabel
Continued efforts to translate ...... trials into clinical practice
@ast
Continued efforts to translate ...... trials into clinical practice
@en
Continued efforts to translate ...... trials into clinical practice
@nl
P2093
P2860
P921
P3181
P1476
Continued efforts to translate ...... trials into clinical practice
@en
P2093
Angelo Avogaro
Enzo Bonora
Gian Paolo Fadini
Giorgio Sesti
Stefano Del Prato
P2860
P2888
P3181
P356
10.1186/S12933-016-0431-4
P407
P577
2016-08-11T00:00:00Z
P6179
1047474174